Find drugs for your specific mutation
Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene. Each person with cystic fibrosis has two CFTR mutations – they can be the same or different. Enter your mutations to find the drugs that could help. The order of your mutations is not important. If you know only one of your mutations, choose “Don't know” for your second mutation.
results for 120del23 / 2869insG
Approved CFTR modulators
KALYDECO
ivacaftor
KALYDECO is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 6 months and older who have at least one mutation in their CF gene that is responsive to KALYDECO.
ORKAMBI
lumacaftor/ivacaftor
ORKAMBI is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 2 years and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene. ORKAMBI should not be used in patients other than those who have two copies of the F508del mutation in their CFTR gene.
SYMDEKO
tezacaftor/ivacaftor and ivacaftor
SYMDEKO is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have two copies of the F508del mutation, or who have at least one mutation in the CF gene that is responsive to treatment with SYMDEKO.
TRIKAFTA
Elexacaftor + tezacaftor + ivacaftor
TRIKAFTA is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.
Treats - 120del23 / 2869insG
| Drug | Phase of research | Number of sources | Average impact factor |
|---|
Treats - General effect
| Drug | Phase of research | Number of sources | Average impact factor |
|---|---|---|---|
| ALX-009 | Phase One Clinical Trial | 1 | 5.11 |
| AquADEKs® | Accessible Dietary Supplement | 3 | 7.22 |
| Mannitol | EMA-approved for Cystic Fibrosis | 3 | 8.79 |
| Levofloxacin | FDA-/EMA-approved for Cystic Fibrosis | 3 | 6.55 |
| Nitric oxide | Phase Two Clinical Trial | 1 | 7.01 |
| OligoG | Phase Two Clinical Trial | 2 | 3.41 |
| Pancrelipase enzyme | FDA-approved for Cystic Fibrosis | 1 | 4.73 |
| Pancrelipase enzyme | FDA-approved for Cystic Fibrosis | 1 | 3.19 |
| Pancrelipase enzyme | FDA-approved for Cystic Fibrosis | 1 | 13.77 |
| Pancrelipase enzyme | FDA-approved for Cystic Fibrosis | 3 | 3.20 |
| pGM169/GL67A | Phase Two Clinical Trial | 1 | 4.29 |
| Polymyxin B | FDA-/EMA-approved for Other Purpose | 1 | 6.27 |
| Recombinant human deoxyribonuclease I | FDA-/EMA-approved for Cystic Fibrosis | 9 | 5.53 |
| SPX-101 | Phase Two Clinical Trial | 2 | 9.77 |
| Tobramycin | FDA-/EMA-approved for Cystic Fibrosis | 2 | 3.19 |
| Vancomycin | Phase Three Clinical Trial | 1 | 2.80 |
| ETX001 | Pre-clinical | 1 | 16.49 |
| Acebilustat | Phase Two Clinical Trial | 1 | 1.95 |
| Alpha 1 Anti-Trypsin | FDA-approved for Other Purpose | 2 | 3.66 |
| Amikacin | FDA-approved for Cystic Fibrosis | 2 | N/A |
| Azithromycin | FDA-approved for Cystic Fibrosis | 4 | 18.51 |
| Aztreonam | FDA-/EMA-approved for Cystic Fibrosis | 6 | 5.76 |
| POL6014 | Phase One Clinical Trial | 1 | 4.29 |
| Gallium | Phase Two Clinical Trial | 2 | 17.16 |
| Docosahexaenoic Acid | Accessible Dietary Supplement | 2 | 3.25 |
| KB001 | Phase Two Clinical Trial | 2 | 3.86 |
| Hypertonic Saline | Therapeutic not approved by FDA or EMA | 6 | 22.30 |
| Ibuprofen | FDA-/EMA-approved for Other Purpose | 4 | 5.79 |
| Lipase | FDA-approved for Cystic Fibrosis | 1 | 3.02 |
Does not treat - 120del23 / 2869insG
| Drug | Phase of research | Number of sources | Average impact factor |
|---|
